

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09780035
Filing Date	2001-02-09
First Named Inventor	Tariq Ghayur
Art Unit	1644
Examiner Name	Gambel, Phillip
Attorney Docket Number	BBC-084/US

Sheet ☐ of ☐**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RG	51	MCINNIS, IAIN B. et al., Interleukin 18: a pleiotropic participant in chronic inflammation, Immunology Today (2000) Vol. 21, pgs. 312-315	
	52	MENDEZ, MICHAEL J. et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics (1997), Vol. 15, 146-156	
	53	MIZUSHIMA, SEIICHI et al., pEF-BOS, a powerful mammalian expression vector, Nucleic Acids Research, (1990) Vol. 18(17), pg. 5322	
	54	MONTELEONE, GIOVANNI et al., Bioactive IL-18 Expression is up-Regulated in Chron's Disease, Journal of Immunology, (1999) Vol. 163(1), pgs. 143-147	
	55	NETEA, MIHAI G. et al., Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation, The Journal of Immunology (2000) Vol. 164, pgs. 2644-2649	
	56	POLJAK, ROBERTO J., Production and Structure of diabodies, Structure (1994), Vol. 2, pgs. 1121-1123	
	57	QUEEN, CARY et al., A human antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci., (1989) Vol. 86, pgs. 10029-10033	
	58	REICHMANN, LUTZ et al., Reshaping human antibodies for therapy, Nature (1988), Vol. 332, pgs. 323-327	
	59	TAKEDA, KIYOSHI et al., Defective Nk Cell Activity and Th1 Response in IL-18 Deficient Mice, Immunity (1998) Vol. 8, pgs. 383-390	
	60	TANIGUCHI, MUTSUOKO et al., Characterization of anti-human interleukin-18 (IL-18), Journal of Immun. Methods (1997) Vol. 206, 107-113	

Examiner Signature	/Phillip Gambel/	Date Considered	12/21/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number 09780035

Filing Date 2001-02-09

First Named Inventor Tariq Ghayur

Art Unit 1644

Examiner Name Gambel, Phillip

Attorney Docket Number BBC-084/US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RG	61	TAYLOR, LISA D. et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immun, Nucleic Acids Research (1992), Vol. 20(23), pgs. 6287-6295	
	62	TISSI, LUCIANA et al., Role of Tumor Necrosis Factor Alpha, Interleukin-1B and Interleukin-6 in a mouse model of Group B . Infection and Immunity (1999), Vol. 67, 4545-4550	
	63	TRENTHAM, DAVID E. et al., Autoimmunity to Type II Collagen: An Experimental Model of Arthritis, Journal of Exp. Med. (1977) Vol. 146, pgs. 857-868	
	64	TSUTSUI, HIROKO et al, Caspase-1 Independent, Fas/Fas/ Ligand-Mediated IL-18 Secretion from Macrophages Causes Acute liver injury in Mice, Immunity (1999) Vol. 11, pgs. 359-367	
	65	TSUTSUI, HIROKO et al, IL-18 Accounts for both TNF-a- and Fas Ligand-Mediated Hepatotoxic Pathways, Jour. of Immun., (1997), Vol. 159(8) pgs. 3961-3967	
	66	URLAUB GAIL et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Pro. Natl. Acad. Sci. (1980) Vol. 77(7), pgs. 4216-4220	
	67	USHIO SHIMPEI et al., Cloning of the cDNA for Human IFN-γ-Inducing Factor, Expression in Escherichia coli, Journal of Immunology (1996) Vol. 156, pgs. 4274-4279	
	68	VAN NOSTRAND, WILLIAM E. et al., Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid B-protein precursor, Nature (1989) Vol. 341, pgs. 546-551	
	69	WILDBAUM, GIZI et al., Neutralizing Antibodies to IF-γ-inducing Factor Prevent Experimental Autoimmune Encephalomyelitis, Jour. of Immun. (1998) Vol. 161(11), pgs. 6368-6374	
RG	70	WINTER, GREG et al., Making Antibodies by Phage Display Technology, Annu. Rev. of Immun. (1994), Vol. 12, pgs. 433-455	

Examiner  
Signature

/Phillip Gambel/

Phillip Gambel

Date

Considered

12/21/2009

05/18/2010

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./